药物对比
Teplizumab vs Pioglitazone
Teplizumab (Tzield) 通过结合 CD3 延缓1型糖尿病发病；Pioglitazone (Actos) 为 TZD，可减轻2型糖尿病的胰岛素抵抗。比较免疫疗法与口服增敏剂。
此页面暂无可用的对比维度。
临床背景
This comparison may arise when distinguishing disease-modifying therapy for type 1 diabetes from insulin-sensitizing treatment for type 2 diabetes.
结论
Teplizumab and Pioglitazone treat different forms of diabetes and cannot be ranked as better or worse.
全部药物对比